Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif

  • Molinos-Albert, Luis Manuel|||0000-0001-5447-6803
  • Bilbao, Eneritz
  • Agulló, Luis
  • Marfil, Sílvia|||0000-0003-0139-5000
  • García Rodríguez, Elisabet
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Nieto-Garai, Jon A.
  • Contreras, F. Xabier
  • Floor, Martin
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Villà Freixa, Jordi|||0000-0002-6359-3929
  • Lorizate, Maier
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
The HIV-1 gp41 Membrane Proximal External Region (MPER) is recognized by broadly neutralizing antibodies and represents a promising vaccine target. However, MPER immunogenicity and antibody activity are influenced by membrane lipids. To evaluate lipid modulation of MPER immunogenicity, we generated a 1-Palmitoyl-2-oleoylphosphatidylcholine (POPC)-based proteoliposome collection containing combinations of phosphatidylserine (PS), GM3 ganglioside, holesterol (CHOL), sphingomyelin (SM) and the TLR4 agonist monophosphoryl lipid A (MPLA). A recombinant gp41-derived miniprotein (gp41-MinTT) exposing the MPER and a tetanus toxoid (TT) peptide that favors MHC-II presentation, was successfully incorporated into lipid mixtures (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Urrea, Víctor|||0000-0002-2577-856X
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Blanco, Pau
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Molinos-Albert, Luis Manuel|||0000-0001-5447-6803
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Avila-Nieto, Carlos
  • Varela, Ismael|||0000-0002-3825-372X
  • Cervera Gracia, Laura|||0000-0002-3639-2793
  • Gutiérrez-Granados, Sònia
  • Segura, Maria Mercedes
  • Gòdia, Francesc|||0000-0002-4060-9887
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineered to maximise the presence of antigen on the VLP surface. An HIV-1 gp41-derived protein (Min), including the C-terminal part of gp41 and the transmembrane domain, was fused to HIV-1 Gag. This resulted in high-density MinGag-VLPs. These VLPs demonstrated to be highly immunogenic in animal models using either a homologous (VLP) or heterologous (DNA/VLP) vaccination regimen, with the latter yielding 10-fold higher anti-Gag and anti-Min antibody titres. Despite these strong humoral responses, immunisation with MinGag-VLPs did not induce neutralising antibodies. Nevertheless, antibodies were predominantly of an IgG2b/IgG2c profile and could efficiently bind CD16-2. Furthermore, we demonstrated that MinGag-VLP vaccination could mediate a functional effect and halt the progression of a Min-expressing tumour cell line in an in vivo mouse model.